diosgenin has been researched along with palbociclib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cai, E; Chen, R; Fu, H; Ke, K; Li, X; Shen, J; Shen, Z; Shi, X; Song, N; Wan, W; Wang, J; Xie, X; Zhang, Q; Zhang, R; Zhang, Z; Zuo, A | 1 |
1 other study(ies) available for diosgenin and palbociclib
Article | Year |
---|---|
Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Humans; Lung Neoplasms; Piperazines; Pyridines; Retinoblastoma Protein; Signal Transduction | 2021 |